quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:55:00·226d
PRRelease
ZyVersa Therapeutics Inc. logo

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

ZVSA· ZyVersa Therapeutics Inc.
Health Care
Original source

Companies

  • ZVSA
    ZyVersa Therapeutics Inc.
    Health Care

Related

  • PR23d
    ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
  • SEC23d
    SEC Form 10-K filed by ZyVersa Therapeutics Inc.
  • SEC49d
    ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC141d
    SEC Form 8-K filed by ZyVersa Therapeutics Inc.
  • SEC155d
    ZyVersa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR155d
    ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
  • SEC155d
    SEC Form 10-Q filed by ZyVersa Therapeutics Inc.
  • SEC160d
    SEC Form NT 10-Q filed by ZyVersa Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022